Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1116)	6/20/2005 10:37:55 PM
From: Galirayo	Read Replies (1) \| Respond to of 3722

[ARQL edit] Bernard .. that white opening Bozu showing today .. that closed above the candle bodies of the last high candle body and the others showing here .. says .. VERY Little R. I'd say it's made it. AH is a crap shoot anyway. Aroon says Strong Trend as does the MAs lined up in Trend .. MACD crossover With Zero Line Crossover says ... GO! stockcharts.com[w,a]dacayiay[dc][pb50!c20!f][vc60][iut!Ua12,26,9!Uv25]&pref=G 7.35 ?? the candle bodies on the weekly is what I'd look at for R now. stockcharts.com[w,a]wacayiay[df][pb50!c20!f][vc60][iut!Ua12,26,9!Uv25]&pref=G

To: Jibacoa who wrote (1116)	7/18/2005 10:05:51 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ARQL Is making a 52 wks. H after it said that preclinical data showed that direct activation of the human checkpoint kinase 2, or Chk2, killed cancer cells. Activating Chk2 in the absence of chemotherapy led to the death of cancer cells."This study showed that the activation of checkpoints independently and directly led to cancer cell death." Checkpoint activation, is the central focus of the company's approach to oncology drugs and the basis for its clinical testing of ARQ 501,which they have partnered with Roche. bigcharts.marketwatch.com ARQL Is expected to have larger losses in 2005 & 2006, but it has around $2.45 in cash/shr with a Debt/Equt around 0.001 a BV above $3 and some $9.7M in + cash flow.<g> Bernard